Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. 2010

Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
Unit of Immunology and Microbiology Environmental and Carcinogenesis, Faculty of Sciences of Bizerte, 7021 Zarzouna, University of 7-November at Carthage, Tunisia.

BACKGROUND The present study was undertaken to relate the co-expression of prostate-associated antigens, PSMA and PSA, with the degree of vascularization in normal and pathologic (hyperplasia and cancer) prostate tissues to elucidate their possible role in tumor progression. METHODS The study was carried out in 6 normal, 44 benign prostatic hyperplastic and 39 cancerous human prostates. Immunohistochemical analysis were performed using the monoclonal antibody CD34 to determine the angiogenic activity, and the monoclonal antibodies 3E6 and ER-PR8 to assess PSMA and PSA expression, respectively. RESULTS In our study we found that in normal prostate tissue, PSMA and PSA were equally expressed (3.7 ± 0.18 and 3.07 ± 0.11). A significant difference in their expression was see in hyperplastic and neoplastic prostates tissues (16.14 ± 0.17 and 30.72 ± 0.85, respectively) for PSMA and (34.39 ± 0.53 and 17.85 ± 1.21, respectively) for PSA. Study of prostate tumor profiles showed that the profile (PSA+, PSMA-) expression levels decreased between normal prostate, benign prostatic tissue and primary prostate cancer. In the other hand, the profile (PSA-, PSMA+) expression levels increased from normal to prostate tumor tissues. PSMA overexpression was associated with high intratumoral angiogenesis activity. By contrast, high PSA expression was associated with low angiogenesis activity. CONCLUSIONS These data suggest that these markers are regulated differentially and the difference in their expression showed a correlation with malignant transformation. With regard to the duality PSMA-PSA, this implies the significance of their investigation together in normal and pathologic prostate tissues.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000954 Antigens, Surface Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated. Cell Surface Antigens,Surface Antigens,Surface Markers, Immunological,Cell Surface Antigen,Immunologic Surface Markers,Markers, Immunological Surface,Surface Antigen,Surface Markers, Immunologic,Antigen, Cell Surface,Antigen, Surface,Antigens, Cell Surface,Immunological Surface Markers,Markers, Immunologic Surface,Surface Antigen, Cell,Surface Antigens, Cell
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
July 2004, Histology and histopathology,
Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
January 1995, Anticancer research,
Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
January 2013, Folia histochemica et cytobiologica,
Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
June 2018, Clinical nuclear medicine,
Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
April 1994, Cancer research,
Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
July 1999, Journal of immunotherapy (Hagerstown, Md. : 1997),
Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
June 1998, Cancer,
Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
January 2022, International journal of molecular sciences,
Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
December 2020, Journal of cutaneous pathology,
Awatef Ben Jemaa, and Yosra Bouraoui, and Sataa Sallami, and Ahmed Banasr, and Nawfel Ben Rais, and Latifa Ouertani, and Yassin Nouira, and Ali Horchani, and Ridha Oueslati
June 2006, Oncology (Williston Park, N.Y.),
Copied contents to your clipboard!